Sino Biological | 實體腫瘤的新興 ADC 標靶抗原

Sino Biological | 實體腫瘤的新興 ADC 標靶抗原

2023.05.05

Sino logo

Sino Biological

Featured Products

Featured Cytokines

CRO Services

Antibody-drug conjugates (ADCs)算是一種新興的抗癌療法,結合化療藥物的細胞毒殺作用與抗體辨識tumor-associated antigens (TAAs)的原理,使ADC成為一種快速增長的實體腫瘤藥物療法。在治療實體腫瘤中,除了 EGFR, FGFR, c-MET, 和HER2 等常見的ADC熱門標的外, EpCAM, TROP-2, CD25,等其他新興標的(Table 1)也正在開發中。
 

Sino Biological能提供ADC標靶抗原相關產品,以協助實體腫瘤ADC治療領域的研究。

Table 1: ADC target antigens at the preclinical and clinical stages

Various categories of ADCs in clinical and preclinical stages

ADC target antigens

Well-established ADC TAAs

HER2, EGFR, EGFRvIII, c-MET, FGFR2, FGFR3

ADC TAAs overexpressed on cancer cells

EpCAM, BCMA, TROP-2, AXL, HER3, CD166, CEACAM5, GPNMB, Mesothelin, CD70

Target antigens in TME

CD25/IL2R, B7-H3, ANTXR1

Target antigens in CSCs

PTK7, ROR1, 5T4

 

Sino Biological提供ADC 治療領域相關高品質產品,產品經活性驗證,也被引用至多篇國際熱門期刊並受到認可。

更多資訊 !

 

ADC 療法相關重組蛋白產品特色

 


High-Purity


HPLC-Verified


High-Acitivity


Cited by Researchers

 

 

Human EGFR Protein

(Cat#: 10001-H27H-B)

Human CD25/IL2R alpha Protein

(Cat#: 10165-H08H)

Immobilized Human EGF (Cat#: 10605-H01H) can bind Human EGFR

Ability to inhibit IL2-induced proliferation of M07e cells

 

Human c-MET Protein

(Cat#: 10692-H08H)

Human BCMA Protein

(Cat#: 10620-H08H)

Immobilized Cynomolgus HGF (Cat#: 90286-CNAH) can bind Human c-MET

Immobilized Human BAFF (Cat#: 10056-H01H) can bind Human BCMA

 

更多資訊

其它相關蛋白

TIM-1

 

EpCAM

 

CD56

 

Ly75

 

Siglec-2

 

Nectin-4

 

CD228

 

ENPP3

 

MUC1

 

Liv1

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!